Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis

BACKGROUND AND OBJECTIVES: This analysis used a population pharmacokinetic approach to identify covariates that influence plasma exposure of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for weight management in overweight and obese individuals. METHODS: Samples for...

Descripción completa

Detalles Bibliográficos
Autores principales: Overgaard, Rune V., Petri, Kristin C., Jacobsen, Lisbeth V., Jensen, Christine B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069304/
https://www.ncbi.nlm.nih.gov/pubmed/27193270
http://dx.doi.org/10.1007/s40262-016-0410-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069304/
https://www.ncbi.nlm.nih.gov/pubmed/27193270
http://dx.doi.org/10.1007/s40262-016-0410-7

Ejemplares similares